Compound Evidence File
#EC-2026-0609
EAPA (ethyl alpha-phenylacetoacetate / ethyl 3-oxo-2-phenylbutanoate) CAS 5413-05-8
Filed under Raw Materials. The bureau holds 123 laboratory returns for this compound from 38 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
38 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 4 | 10.0 | 9.9 | 10.0 | 22 Mar 2026 | 3 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 10.0 | 10.0 | 10.0 | 14 Mar 2026 | 8 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 10.0 | 9.9 | 10.0 | 6 May 2026 | 16 Aug 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 12 Nov 2025 | 24 Jan 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Apr 2026 | 15 May 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 28 Mar 2026 | 2 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 10.0 | 9.9 | 10.0 | 22 Nov 2025 | 14 Jun 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 10.0 | 9.9 | 10.0 | 28 Feb 2026 | 16 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 9.9 | 10.0 | 1 May 2026 | 19 Aug 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 10.0 | 10.0 | 10.0 | 28 Feb 2026 | 15 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 24 May 2026 | 14 Jun 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 2 Dec 2025 | 26 Apr 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Nov 2025 | 22 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 9.9 | 9.9 | 10.0 | 6 Jan 2026 | 8 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 18 May 2026 | 24 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Mar 2026 | 28 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 16 Mar 2026 | 28 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 1 Jan 2026 | 28 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 21 Jan 2026 | 27 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Jan 2026 | 18 Feb 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Mar 2026 | 1 Jun 2026 |
| Glamgurcraft Innovations Foreign TradeCASE #VI-2026-0348 | X | 1 | 9.9 | 9.9 | 9.9 | 8 Jul 2025 | 8 Jul 2025 |
| HkRoidsCASE #VI-2026-0784 | X | 1 | 9.6 | 9.6 | 9.6 | 3 Jun 2025 | 3 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.9 | 8.5 | 9.4 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.5 | 6.6 | 10.0 | 21 May 2026 | 21 May 2026 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 4 | 8.5 | 8.1 | 8.7 | 13 Jun 2025 | 20 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.4 | 6.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 8.4 | 7.4 | 9.8 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.3 | 7.9 | 8.9 | 24 May 2026 | 24 May 2026 |
| ZhuoYan labCASE #VI-2026-0902 | X | 1 | 7.8 | 7.8 | 7.8 | 24 Apr 2025 | 24 Apr 2025 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 1 | 7.4 | 7.4 | 7.4 | 13 Jun 2025 | 13 Jun 2025 |
| EHZ PeptidesCASE #VI-2026-0296 | C | 3 | 6.6 | 6.5 | 6.8 | 28 Mar 2025 | 25 May 2026 |
| Orbitrex PeptidesCASE #VI-2026-0812 | X | 1 | 6.4 | 6.4 | 6.4 | 2 Apr 2025 | 2 Apr 2025 |
| Skye PeptidesCASE #VI-2026-0451 | X | 1 | 5.7 | 5.7 | 5.7 | 8 Jul 2025 | 8 Jul 2025 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 5.3 | 5.3 | 5.3 | 9 Jun 2025 | 9 Jun 2025 |
| Wolverine PeptidesCASE #VI-2026-0262 | X | 1 | 5.2 | 5.2 | 5.2 | 6 May 2025 | 6 May 2025 |
Open any subject to view the batch-level evidence for EAPA (ethyl alpha-phenylacetoacetate / ethyl 3-oxo-2-phenylbutanoate) CAS 5413-05-8 alone.